Citations

Clear

8 citation(s) found for "Seger, PR".

Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Lemaı̂tre, F. , Barten, Markus J. , Bergan, Stein , Shipkova, Maria , Vinks, Sander, Wieland, Eberhard , Bornemann-Kolatzki, Kirsten , Brunet, Mercè , Winter, Brenda C. M. de , Ito, Taihei, Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lawson, Roland , Lloberas, Núria , Marquet, Pierre , Millán, Olga , Mizuno, Tomoyuki , Noceti, Ofelia , Oellerich, Michael , Pattanaik, Smita , Seger, Christoph , Schaik, Ron HN van , Venkataramanan, Raman , Walson, Phil, Woillard, Jean‐Baptiste , Langman, Loralie J., Masuda, Satohiro , Lemaitre, Florian, Gelder, Teun van , Vinks, Sander, Dieterlen, Maja‐Theresa , Elens, Laure , Moes, Dirk Jan A. R. , Pawiński, Tomasz , Walson, Philip D.

Mayo Clinic

Therapeutic Drug Monitoring | September 27, 2024 | Volume: 47 | Issue: 1 | Pages: 4-31

10.1097/ftd.0000000000001250 | PMID 39331837 Get It

Abstract: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Bergan, Stein , Hesselink, Dennis A. , Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lemaı̂tre, F. , Marquet, Pierre , Molinaro, Mariadelfina , Noceti, Ofelia , Pattanaik, Smita , Seger, Christoph , Shipkova, Maria , Swen, Jesse J. , Gelder, Teun van , Venkataramanan, Raman , Wieland, Eberhard , Woillard, Jean‐Baptiste , Zwart, Tom C. , Barten, M.J., Budde, Klemens , Haufroid, Vincent , Millán, Olga , Mizuno, Tomoyuki , Oellerich, Michael , Salzmann, Linda, Tönshoff, Burkhard , Schaik, Ron H. N. van , Vethe, Nils Tore , Vinks, Alexander A. , Wallemacq, Pierre, Åsberg, Anders , Langman, Loralie J., Budde, Klemens , Brunet, Merçè , Pawiński, Tomasz , Dieterlen, Maja‐Theresa , Elens, Laure , Masuda, Satohiro , Moes, Dirk Jan A. R. , Picard, Nicolas

Mayo Clinic

Therapeutic Drug Monitoring | March 12, 2021 | Volume: 43 | Issue: 2 | Pages: 150-200

10.1097/ftd.0000000000000871 | PMID 33711005 Get It

Abstract: When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under the curve based on the measurement of drug concentrations in only a few samples. This approach is feasible in the clinical routine and has proven successful in terms of correlation with outcome. However, the search for superior correlates has continued, and numerous studies in search of biomarkers that could better predict the perfect dosage for the individual patient have been published. As it was considered timely for an updated and comprehensive presentation of consensus on the status for personalized treatment with MPA, this report was prepared following an initiative from members of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Topics included are the criteria for analytics, methods to estimate exposure including pharmacometrics, the potential influence of pharmacogenetics, development of biomarkers, and the practical aspects of implementation of target concentration intervention. For selected topics with sufficient evidence, such as the application of limited sampling strategies for MPA area under the curve, graded recommendations on target ranges are presented. To provide a comprehensive review, this report also includes updates on the status of potential biomarkers including those which may be promising but with a low level of evidence. In view of the fact that there are very few new immunosuppressive drugs under development for the transplant field, it is likely that MPA will continue to be prescribed on a large scale in the upcoming years. Discontinuation of therapy due to adverse effects is relatively common, increasing the risk for late rejections, which may contribute to graft loss. Therefore, the continued search for innovative methods to better personalize MPA dosage is warranted.
Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology,
Apovian, Caroline M., Brethauer, Stacy A., Joffe, Aaron M. , Kushner, Robert F. , Lindquist, R R , Pessah‐Pollack, Rachel , Seger, Jennifer, Adams, Stephanie, Cleek, John B., Correa, Riccardo , Figaro, M. Kathleen, Flanders, Karen, Grams, Jayleen , Hurley, Daniel L. , Kothari, Shanu N. , Seger, Michael, Still, Christopher D. , Mechanick, Jeffrey I. , Garvey, William Timothy , Kim, Julie , Lindquist, Richard, Urman, Richard D , Seger, Michael V.

Mayo Clinic

Obesity | March 23, 2020 | Volume: 28 | Issue: 4 | Pages: No page available

10.1002/oby.22719 | PMID 32202076 Get It

Objective The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association of Clinical Endocrinologists (AACE), The Obesity Society (TOS), American Society for Metabolic and Bariatric Surgery (ASMBS), Obesity Medicine Association (OMA), and American Society of Anesthesiologists (ASA) Boards of Directors in adherence with the AACE 2017 protocol for standardized production of CPGs, algorithms, and checklists. Methods Each recommendation was evaluated and updated based on new evidence from 2013 to the present and subjective factors provided by experts. Results New or updated topics in this CPG include: contextualization in an adiposity‐based chronic disease complications‐centric model, nuance‐based and algorithm/checklist‐assisted clinical decision‐making about procedure selection, novel bariatric procedures, enhanced recovery after bariatric surgery protocols, and logistical concerns (including cost factors) in the current health care arena. There are 85 numbered recommendations that have updated supporting evidence, of which 61 are revised and 12 are new. Noting that there can be multiple recommendation statements within a single numbered recommendation, there are 31 (13%) Grade A, 42 (17%) Grade B, 72 (29%) Grade C, and 101 (41%) Grade D recommendations. There are 858 citations, of which 81 (9.4%) are evidence level (EL) 1 (highest), 562 (65.5%) are EL 2, 72 (8.4%) are EL 3, and 143 (16.7%) are EL 4 (lowest). Conclusions Bariatric procedures remain a safe and effective intervention for higher‐risk patients with obesity. Clinical decision‐making should be evidence based within the context of a chronic disease. A team approach to perioperative care is mandatory, with special attention to nutritional and metabolic issues.
Functional control of electrophysiological network architecture using direct neurostimulation in humans
Khambhati, Ankit N. , Costantini, Julia , Ezzyat, Youssef , Solomon, Ethan A. , Jobst, Barbara C. , Sheth, Sameer A. , Seger, Sarah , Weiss, Shennan A. , Sperling, Michael R. , Gorniak, Richard , Rizzuto, Daniel S. , Kahana, Michael J. , Lucas, Timothy H., Bassett, Danielle S. , Sperling, Michael R , Weiss, Shennan A , Kahn, Ari E. , Gross, Robert E. , Zaghloul, Kareem A. , Worrell, Gregory A. , Lega, Bradley Charles , Das, Sandhitsu R. , Stein, Joel M. , Davis, Kathryn A. , Tracy, Joseph I. , Jobst, Barbara

Mayo Clinic

Network Neuroscience | May 28, 2019 | Volume: 3 | Issue: 3 | Pages: 848-877

10.1162/netn_a_00089 | PMID 31410383 Get It

Chronically implantable neurostimulation devices are becoming a clinically viable option for treating patients with neurological disease and psychiatric disorders. Neurostimulation offers the ability to probe and manipulate distributed networks of interacting brain areas in dysfunctional circuits. Here, we use tools from network control theory to examine the dynamic reconfiguration of functionally interacting neuronal ensembles during targeted neurostimulation of cortical and subcortical brain structures. By integrating multimodal intracranial recordings and diffusion-weighted imaging from patients with drug-resistant epilepsy, we test hypothesized structural and functional rules that predict altered patterns of synchronized local field potentials. We demonstrate the ability to predictably reconfigure functional interactions depending on stimulation strength and location. Stimulation of areas with structurally weak connections largely modulates the functional hubness of downstream areas and concurrently propels the brain towards more difficult-to-reach dynamical states. By using focal perturbations to bridge large-scale structure, function, and markers of behavior, our findings suggest that stimulation may be tuned to influence different scales of network interactions driving cognition.
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, Mercè , Gelder, Teun van , Åsberg, Anders , Haufroid, Vincent , Hesselink, Dennis A. , Langman, Loralie J., Lemaı̂tre, F. , Marquet, Pierre , Seger, Christoph , Shipkova, Maria , Vinks, Alexander A. , Wallemacq, Pierre, Wieland, Eberhard , Woillard, Jean‐Baptiste , Barten, Markus J. , Budde, Klemens , Colom, Helena , Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Mathew, Binu , Millán, Olga , Mizuno, Tomoyuki , Monchaud, Caroline , Noceti, Ofelia , Picard, Nicolas , Schaik, Ron HN van , Sommerer, Claudia , Vethe, Nils Tore , Winter, Brenda C. M. de , Christians, Uwe , Bergan, Stein , Langman, Loralie, Budde, Klemens , Dieterlen, Maja‐Theresa , Elens, Laure , MacPhee, Iain A. M. , Masuda, Satohiro , Moes, Dirk Jan A. R. , Pawiński, Tomasz

Mayo Clinic

Therapeutic Drug Monitoring | April 30, 2019 | Volume: 41 | Issue: 3 | Pages: 261-307

10.1097/ftd.0000000000000640 | PMID 31045868 Get It

Abstract: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT) decided to issue an updated consensus report considering the most relevant advances in tacrolimus pharmacokinetics (PK), pharmacogenetics (PG), pharmacodynamics, and immunologic biomarkers, with the aim to provide analytical and drug-exposure recommendations to assist TDM professionals and clinicians to individualize tacrolimus TDM and treatment. The consensus is based on in-depth literature searches regarding each topic that is addressed in this document. Thirty-seven international experts in the field of TDM of tacrolimus as well as its PG and biomarkers contributed to the drafting of sections most relevant for their expertise. Whenever applicable, the quality of evidence and the strength of recommendations were graded according to a published grading guide. After iterated editing, the final version of the complete document was approved by all authors. For each category of solid organ and stem cell transplantation, the current state of PK monitoring is discussed and the specific targets of tacrolimus trough concentrations (predose sample C 0 ) are presented for subgroups of patients along with the grading of these recommendations. In addition, tacrolimus area under the concentration–time curve determination is proposed as the best TDM option early after transplantation, at the time of immunosuppression minimization, for special populations, and specific clinical situations. For indications other than transplantation, the potentially effective tacrolimus concentrations in systemic treatment are discussed without formal grading. The importance of consistency, calibration, proficiency testing, and the requirement for standardization and need for traceability and reference materials is highlighted. The status for alternative approaches for tacrolimus TDM is presented including dried blood spots, volumetric absorptive microsampling, and the development of intracellular measurements of tacrolimus. The association between CYP3A5 genotype and tacrolimus dose requirement is consistent (Grading A I). So far, pharmacodynamic and immunologic biomarkers have not entered routine monitoring, but determination of residual nuclear factor of activated T cells–regulated gene expression supports the identification of renal transplant recipients at risk of rejection, infections, and malignancy (B II). In addition, monitoring intracellular T-cell IFN-g production can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II). Although cell-free DNA seems a promising biomarker of acute donor injury and to assess the minimally effective C 0 of tacrolimus, multicenter prospective interventional studies are required to better evaluate its clinical utility in solid organ transplantation. Population PK models including CYP3A5 and CYP3A4 genotypes will be considered to guide initial tacrolimus dosing. Future studies should investigate the clinical benefit of time-to-event models to better evaluate biomarkers as predictive of personal response, the risk of rejection, and graft outcome. The Expert Committee concludes that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade. Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacrolimus therapy and to improve long-term outcomes for treated patients.
Negligible Thyroid Hormone Content Present in Nonprescription U.S. Weight Loss Products
Seger, Christian, He, Xuemei , Bernet, Victor , Rhee, Connie M. , Leung, Angela M. , Bernet, Victor J, Braverman, Lewis E. , Yeh, Michael W. , Singh, Ravinder J. , Leung, Angela M

Mayo Clinic

Thyroid® | November 29, 2016 | Volume: 27 | Issue: 2 | Pages: 300-301

10.1089/thy.2016.0534 | PMID 27897088 Get It

Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype
Hoppman‐Chaney, Nicole L., Wain, KE, Seger, PR, Dw, Superneau, Hodge, J.C., Superneau, Duane W.

Mayo Clinic

Clinical Genetics | July 9, 2012 | Volume: 83 | Issue: 4 | Pages: 345-351

10.1111/j.1399-0004.2012.01925.x | PMID 22775350 Get It

The 15q13.3 microdeletion syndrome (OMIM #612001) is characterized by a wide range of phenotypic features, including intellectual disability, seizures, autism, and psychiatric conditions. This deletion is inherited in approximately 75% of cases and has been found in mildly affected and normal parents, consistent with variable expressivity and incomplete penetrance. The common deletion is approximately 2 Mb and contains several genes; however, the gene(s) responsible for the resulting clinical features have not been clearly defined. Recently, four probands were reported with small deletions including only the CHRNA7 gene. These patients showed a wide range of phenotypic features similar to those associated with the larger 15q13.3 microdeletion. To further correlate genotype and phenotype, we queried our database of >15,000 patients tested in the Mayo Clinic Cytogenetics Laboratory from 2008 to 2011 and identified 19 individuals (10 probands and 9 family members) with isolated heterozygous CHRNA7 gene deletions. All but two infants displayed multiple features consistent with 15q13.3 microdeletion syndrome. We also identified the first de novo deletion confined to CHRNA7 as well as the second known case with homozygous deletion of CHRNA7 only. These results provide further evidence implicating CHRNA7 as the gene responsible for the clinical findings associated with 15q13.3 microdeletion.
Safety and Efficacy of Vardenafil for the Treatment of Men With Erectile Dysfunction After Radical Retropubic Prostatectomy
Brock, Gerald, Nehra, Ajay, Lipshultz, Larry I. , Karlin, Gary, Seger, Monica, Padma-Nathan, Harin, Gleave, Martin

Mayo Clinic

Journal of Urology | November 18, 2003 | Volume: 170 | Issue: 4 Part 1 | Pages: 1278-1283

10.1097/01.ju.0000086947.00547.49 | PMID 14501741 Get It